Lv11
10 积分 2022-11-04 加入
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
10小时前
待确认
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan
10小时前
求助中
SACI-IO HR+ full paper Annals of Oncology 2026 Garrido-Castro sacituzumab govitecan pembrolizumab HR HER2 metastatic breast cancer
2天前
求助中
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
2天前
已完结
Resistance to antibody-drug conjugates: A review
5天前
已完结
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity
5天前
已完结
Exploring the next generation of antibody-drug conjugates
5天前
已完结
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
5天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
5天前
已完结
皖公网安备34019202002308
